Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges
Kristin Bittenbender of Genentech has been appointed as the new chair of the Biotechnology Innovation Organization (BIO) board for the 2025-2026 term1.
Frank Watanabe of Arcutis Bio was named vice-chair for the same term1.
This leadership change comes at a time when the biotech industry faces significant existential threats, despite a generally receptive regulatory environment from the FDA1.
BIO 2025 is addressing industry challenges with over 100 interactive sessions, including focus areas such as biotherapeutics innovation, policy, and business development4.
The new leadership is expected to steer BIO through ongoing challenges, emphasizing the importance of regulatory science, advocacy, and innovation in navigating current uncertainties14.
Sources:
1. https://pharmaphorum.com/news/genentechs-bittenbender-named-board-chair-bio